What You Need to Know About MRD for AML: The Basics | Dr. Tian Zhang #AML

(1:2:16)

MRD for acute leukemias: opinion from both sides of the Atlantic

(6:42)

Improving the use of MRD for the prognosis and treatment of ALL

(1:52)

Multiomics Profiling of MRD for Understanding the Biology of Ultra-Drug Resistance in Myeloma

(7:31)

The possible benefits of tumor-informed MRD for patients with sarcoma

(1:1econd)

Sustained MRD for treatment guidance in myeloma

(47)

The evolution of MRD for myeloma

(3:15)

MRD for multiple myeloma: is it ready for prime-time?

(52)

UNDERSTAND ROYAL Q SETTINGS AND MARKET ANALYSIS WITH COACH MRD

(18:53)

The utility of MRD for predicting treatment outcomes in patients with CLL

(1:36)

Are we ready to use MRD for treatment decisions in patients with MM?

(11:32)

MRD for decision making in follicular lymphoma

(2:13)

Dr Lindsey Roeker on Using MRD for Decision Making

(1:21)

Debate on the use of MRD for multiple myeloma management

(13:8)

Minimal Residual Disease (MRD) | High Impact Topic (HIT)

(4:44)

What is MRD? #myeloma

(7:42)

The relevance of MRD for CLL in the era of targeted therapies

(1:22)

Utilizing MRD for AML in the clinical setting

(19:31)

How is MRD testing done?

(8:53)

Does everyone need to become MRD negative to have good outcomes?

(4:54)